|

Anti-FLT3 CAR-T cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: HG-CT-1

Pipeline

Phase 1: 1

Top Sponsors

  • Hemogenyx Pharmaceuticals LLC1

Indications

  • Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)1
  • Cancer1

Houston, Texas1 trial

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

MD Anderson

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.